Skip to content

Serotonin: all studies

Page 364 of 400: studies 3,631 to 3,640 of 3,999, newest first. Back to the serotonin overview

Research

Electroconvulsive therapy in the treatment of depression in a former ecstasy user

Journal of Psychopharmacology November 1, 2006 Roland W. Freudenmann, Carlos Schönfeldt-lecuona, Manfred Spitzer et al. 4 citations

Depression in former ecstasy users may not respond to selective serotonin reuptake inhibitors (SSRIs) possibly due to damaged serotonergic synapses following long-term heavy ecstasy use. We report findings in a patient suffering from MDMA-induced depression which was refractory to several antidepressive medications including selective noradrenergic reuptake inhibitor (SNRI) and SSRI. An add-on...

A developmental comparison of the neurobehavioral effects of ecstasy (MDMA)

Neurotoxicology and Teratology October 21, 2006 Brian J. Piper 54 citations

The entactogen +/-3,4-methylenedioxymethamphetamine (MDMA or ecstasy) is a popular recreational drug among college, high school, and, occasionally, middle school students. Preclinical research examining the acute and long-term effects of MDMA has predominately been conducted in reproductively mature subjects but there has been increasing interest in adolescent and in utero exposure. This review...

DOI: 10.1016/j.ntt.2006.10.002 (opens in new tab) MDMA Ecstasy Neurochemical Developmental psychology +1

DESIGNER DRUGS AS A CAUSE OF HOMICIDE

Addiction October 10, 2006 Toshihiko Matsumoto, Takayuki Okada 29 citations

'Foxy' is a widely used street name for a hallucinogenic drug containing the tryptamine derivative 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT). The US Drug Enforcement Administration classified 5-MeO-DIPT as a Schedule I substance in 2004 [1]; the Japanese Ministry of Health, Labour and Welfare has also restricted this substance since April 2005, according to the Narcotics and...

DOI: 10.1111/j.1360-0443.2006.01573.x (opens in new tab) Psilocybin Designer drug Hallucinogen Euphoriant +1

Modulation of high alcohol drinking in the inbred Fawn-Hooded (FH/Wjd) rat strain: implications for treatment.

Addiction Biology September 1, 2006 David H Overstreet, Amir H Rezvani, Michael Cowen et al. 19 citations

The Fawn-Hooded rat (FH/Wjd) is an inbred alcohol-preferring rat strain, unlike most of the other strains that were selectively bred for high alcohol intake and preference. It was chosen for study some 16 years ago because of a reported mutation that disrupted platelet serotonin function. Although the FH/Wjd rat has high alcohol intake (>5 g/kg/day) and preference (>65%), interbreeding with an...

Nature-inspired indolyl-2-azabicyclo[2.2.2]oct-7-ene derivatives as promising agents for the attenuation of withdrawal symptoms: synthesis of 20-desethyl-20-hydroxymethyl-11-demethoxyibogaine.

Natural Product Research July 10, 2006 Daniele Passarella, A Barilli, Simon M. N. Efange et al. 4 citations

Microwave assisted Diels-Alder cycloaddition of 5-Br-N-benzylpyridinone (2) with methyl acrylate is described to gain an easy access to 7-bromo-2-benzyl-3-oxo-2-aza-5 or 6-carbomethoxy bicyclo[2.2.2]oct-7-enes (3)-(6). The preparation of the ibogaine analogue 20-desethyl-(20-endo)-hydroxymethyl-11-demethoxyibogaine (17) is described by stereoselective hydrogenation of the C(7)-C(8) double bond....

DOI: 10.1080/14786410500160645 (opens in new tab) Full text (opens in new tab) Addiction treatment Withdrawal management Substance abuse therapy Drug recovery +28

Elevated impulsivity and impaired decision-making in abstinent Ecstasy (MDMA) users compared to polydrug and drug-naïve controls.

Neuropsychopharmacology July 2006 Michael John Morgan, Lara Chiara Impallomeni, Alessandro Pirona et al.

Ecstasy (MDMA; 3,4-methylenedioxymethamphetamine) has a well-recognized neurotoxic effect on central serotonergic (5-HT) systems in animals, and there is some evidence of persistent serotonergic dysregulation in human ecstasy users. Serotonin is believed to mediate impulsive behavior and effective decision-making. Thus, the aim of the present study was to investigate impulsive behavior and...

Effects of repeated phencyclidine administration on adult hippocampal neurogenesis in the rat.

Synapse July 1, 2006 Juan Liu, Toshihito Suzuki, Tatsunori Seki et al.

Dysfunctional maturation of neural networks, particularly hippocampus-prefrontal networks, may be of particular interest in determining the pathophysiology of schizophrenia. Phencyclidine (PCP)-induced symptoms in humans appear to offer a more complete model of schizophrenia than do amphetamine-induced symptoms. This study investigated the effects of intermittent i.p. injections of PCP (7.5...

An examination of the effects of 5-Methoxy-n, n-di(ISO)propyltryptamine hydrochloride (Foxy) on cognitive development in rats.

Psychological Reports June 1, 2006 David M. Compton, Melissa C. Selinger, Erin K Testa et al. 16 citations

The hallucinogenic "designer drug" known as Foxy or Methoxy Foxy and formally know as 5-Methoxy-N,N-di(iso)propyltryptamine hydrochloride (5-MeO-DIPT) is rapidly gaining popularity among recreational users. However, little is known about the consequences of its use on neuropsychological development or behavior. During one of two adolescent periods, the rats were given repeated injections of...

Effects of psilocybin on time perception and temporal control of behaviour in humans

Journal of Psychopharmacology May 20, 2006 Marc Wittmann, Olivia Carter, Felix Hasler et al. 245 citations

Hallucinogenic psilocybin is known to alter the subjective experience of time. However, there is no study that systematically investigated objective measures of time perception under psilocybin. Therefore, we studied dose-dependent effects of the serotonin (5-HT) 2A/1A receptor agonist psilocybin (4-phosphoryloxy-N, N-dimethyltryptamine) on temporal processing, employing tasks of temporal...

DOI: 10.1177/0269881106065859 (opens in new tab) Psilocybin Time perception Cognition Hallucinogen +4

Recreational ecstasy use and depression.

Journal of Psychopharmacology May 2006 Casey R. Guillot, David Greenway

Research in laboratory animals has shown that 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) destroys serotonergic axons in the brain at certain doses. Serotonin is known to take part in the regulation of mood in humans. Many researchers have hypothesized that if recreational ecstasy use destroys serotonergic axons, then a corresponding decline in the mood of ecstasy users should be seen....